Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
aragonpharm.com

See what CB Insights has to offer

Founded Year

2009

Stage

Acquired | Acquired

Total Raised

$122M

Valuation

$0000 

About Aragon Pharmaceuticals

Aragon Pharmaceuticals is a small-molecule drug discovery company focused on developing medicines for the treatment of hormonally-driven cancers. These cancers eventually become resistant to existing 1st generation antihormonal therapies, and follow-up treatments are largely ineffective or toxic. The company's lead compound, ARN-509, is an antiandrogen undergoing a Phase I/II clinical trial in patients with progressive, advanced castration-resistant prostate cancer. In addition to ARN-509, Aragon is advancing several compounds designed to both block and destroy hormone receptors that drive tumor growth. These agents should be effective in all stages of endocrine driven tumors including prostate and breast cancer and have potential in treating endometrial and ovarian cancer. The agents offer an opportunity to be superior to 1st generation anti-hormonal agents and therefore provide the opportunity for Aragon to expand its pipeline to early stage disease.In August 2013, Aragon Pharmaceuticals was acquired by Johnson & Johnson. The valuation of Aragon Pharmaceuticals was $650 million. Other terms of the deal were not released.

Aragon Pharmaceuticals Headquarter Location

12780 El Camino Real Suite 301

San Diego, California, 92130,

United States

858-334-4830

Latest Aragon Pharmaceuticals News

UPDATED: Aragon begets Seragon as VCs bankroll $30M cancer drug spinoff

Jan 17, 2019

Richard Heyman, CEO of Aragon Pharmaceuticals Now that Johnson & Johnson ($JNJ) has wrapped up the $1 billion acquisition of Aragon and its next-gen treatment for castration-resistant prostate cancer, the biotech's founders can devote themselves to a new startup that now has a $30 million venture bankroll to work with. CEO Rich Heyman and his team have launched Seragon, the son of Aragon which is developing ARN-810 for breast cancer. And he has some familiar faces in the venture team backing him, with venBio, Topspin Fund, Aisling Capital, OrbiMed Advisors and The Column Group stepping up to contribute to the Series A. The biotech has set out to build a pipeline of selective estrogen receptor degraders for various cancers. J&J cherry-picked ARN-509 for CRPC in its deal, cleanly scooping up complete control of the program and leaving the team to spin out a new company with the rest of the assets. ARN-810 had already begun a Phase I study at the time of the buyout. ARN-509 attracted a significant amount of buzz early on. The treatment was discovered by a team of scientists led by Charles Sawyer, a Howard Hughes Medical Institute investigator who is credited with the discovery of the recently approved Xtandi, another prostate cancer treatment that was heralded as a potential game changer at Medivation ($MDVN). Sawyer sometimes referred to ARN-509 as the "Son of Medivation," and a number of observers have indicated that it could have a blockbuster future if it can survive the clinical trial process. Seragon launches with a team of 22 staffers, all legacy hires with one exception, says Trisha Millican, the former finance chief at Aragon who made the jump to the spinoff. That's a good size for the company for the next year or so, she adds, noting that Sawyer will also stay on as a scientific adviser to the company. Millican also adds that a Phase II study for 810--originally developed in an in-house program--could get underway in late 2014, with plans for an IND on one of their preclinical programs making progress. Don't look for any deals in the near-term, Millican tells FierceBiotech. "We plan to keep this in-house for awhile," says Millican, "until we see additional progress, meaningful success. And that's what this team is really good at." - here's the press release

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aragon Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aragon Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Aragon Pharmaceuticals Patents

Aragon Pharmaceuticals has filed 36 patents.

The 3 most popular patent topics include:

  • Antiandrogens
  • Androgens and anabolic steroids
  • Androstanes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/28/2020

11/2/2021

Androgens and anabolic steroids, Androstanes, Antiandrogens, Prodrugs, Hepatotoxins

Grant

Application Date

5/28/2020

Grant Date

11/2/2021

Title

Related Topics

Androgens and anabolic steroids, Androstanes, Antiandrogens, Prodrugs, Hepatotoxins

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.